Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical... March 2, 2021 Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... August 25, 2021 EMA Adopts Positive Opinion for Pemetrexed Baxter November 3, 2022 The 10-year cancer plan: is improving cancer survival still a priority... December 8, 2022 Load more HOT NEWS Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib
